Journal article
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
Abstract
BACKGROUND: GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and can also have kidney benefits. However, whether GLP-1 receptor agonists improve clinically important kidney outcomes remains uncertain. We aimed to comprehensively assess the effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes by performing a meta-analysis of randomised controlled trials.
METHODS: For this …
Authors
Badve SV; Bilal A; Lee MMY; Sattar N; Gerstein HC; Ruff CT; McMurray JJV; Rossing P; Bakris G; Mahaffey KW
Journal
The Lancet Diabetes & Endocrinology, Vol. 13, No. 1, pp. 15–28
Publisher
Elsevier
Publication Date
January 2025
DOI
10.1016/s2213-8587(24)00271-7
ISSN
2213-8587